IDT Biologika
 |
|
| GmbH | |
| Industry | Pharmaceuticals |
| Founded | 1 July 1921 |
| Headquarters | Dessau-Rosslau, Germany |
|
Key people
|
Dr. Ralf Pfirmann (CEO), Andreas Kastenbauer (Managing Director) |
| Revenue | €172 million (2014) |
|
Number of employees
|
1400 (2015) |
| Website | www |
IDT Biologika is a German biopharmaceutical company with headquarters in Dessau-Rosslau. It develops and produces biotechnology-based vaccines and pharmaceuticals. The company is a member of the Klocke Group.
In 2014 IDT Biologika employed around 1250 people and registered sales of €172 million. The company invests around 8% of its revenue in research and development of proprietary products each year. Company sites in Germany include the BioPharmaPark in Dessau-Rosslau and the Riems district of Greifswald. The IDT sales offices in the US, Denmark, the Netherlands, France and Spain are focused on the animal health business segment. IDT Biologika is active in the animal health, vaccines, pharmaceuticals and quality control business areas.
The company is subject to inspection by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
On July 1, 1921, Friedrich Richter founded Bakteriologisches Institut der Anhaltischen Kreise in Dessau. The Institute was devoted, among other things, to the detection and diagnosis of tuberculosis in humans and animals. On April 1, 1924, Ludwig Wolters took over direction of the Institute, which continued to develop into a health protection center until 1945. Production of the first vaccines, serums and pesticides began during this period, as did the production of immune serums against swine erysipelas. Anhaltische Serum-Institut GmbH Dessau (ASID) was founded on May 31, 1930 under the direction of Wolters and Herbert Hoffmann. Along with the production of serums and vaccines against animal diseases, the institute also worked on bacterial pest control as well as research and control of sheep blackleg.
The health institute was converted to a public law company on November 3, 1933, henceforth under the supervision of the Anhaltian State Ministry and dedicated to the sovereign functions of public healthcare and protecting the livestock population for the state of Anhalt and the German Reich.
The company was granted the status of a scientific research institute on April 9, 1947. The institute was renamed VEB Serum-Werk Dessau on January 1, 1951, and was a key vaccine and medication manufacturer for veterinary and human vaccines in the GDR. Following a decision by the GDR Council of Ministers (1950–1954), Serum-Werk Dessau was assigned directly to the Agriculture and Forestry Ministry on July 1, 1953. On January 1, 1954, the production-oriented VEB Serum-Werk Dessau became the science-oriented Forschungsinstitut für Impfstoffe Dessau. The Institute was mandated to produce vaccines for all major infectious animal diseases, for the GDR and for export. In the field of human medicine, new or improved preparations were developed, such as tuberculin and serums against tetanus and diphtheria. On January 23, 1973, Wilfried Heinicke, former director of the veterinary department of the Agriculture, Forestry and Food Products Ministry, became the new director of the Institute. While the Forschungsinstitut für Impfstoffe primarily focused on basic and applied research and the development of vaccines, serums and diagnostic methods for veterinary and human medicine during the years from 1954 to 1973, now exploration of the immunological foundations of bacterial animal diseases, applied vaccine research and also research on vaccine production technology intensified. In 1985 the Institut für Impfstoffe Dessau had close to 1,500 employees.
...
Wikipedia